1. Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.167
Figure 3 JAKs are composed of several key domains including a tyrosine kinase domain, pseudokinase domain, FERM (band four-point-one, ezrin, radixin, moesin) domain, and SH2 (Src homology 2) domain
Figure 3 | JAKs are composed of several key domains including a tyrosine kinase domain, pseudokinase domain, FERM (band four-point-one, ezrin, radixin, moesin) domain, and SH2 (Src homology 2) domain. The tyrosine kinase domain binds ATP hydrolysing it to ADP and catalyses both autophosphorylation and other substrates including signal transducers and activators of transcription (STATs). JAK, Janus kinase (JAK) inhibitors (Jakinibs) bind to the pocket ordinarily occupied by ATP, thereby preventing JAKs from using ATP and phosphorylating their substrates.
Schwartz, D. M. et al. (2015) Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Nat. Rev. Rheumatol. doi: /nrrheum